NAV

rhGAD65

Identification

Generic Name
rhGAD65
DrugBank Accession Number
DB04963
Background

rhGAD65 (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Recombinant
Synonyms
  • Recombinant human GAD65
  • Recombinant human glutamate decarboxylase 2
  • Recombinant human glutamic acid decarboxylase
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Investigated for use/treatment in diabetes mellitus type 1.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

The immune system of patients treated with rhGAD65 demonstrate an increase in the secretion of several immunomodulatory substances, dominated by regulatory cytokines, including IL5, IL13, IL10, IL17, IFN-a and TNF-a. Additionally, the activity of T-cells in response to GAD65 is increased with rhGAD65 therapy and subjects receiving rhGAD65 show an up regulation of cytokines in response to GAD65.

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Diamyd

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
I7YY5T4995
CAS number
Not Available

References

General References
  1. Bekris LM, Jensen RA, Lagerquist E, Hall TR, Agardh CD, Cilio CM, Lethagen AL, Lernmark A, Robertson JA, Hampe CS: GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination. Diabet Med. 2007 May;24(5):521-6. Epub 2007 Mar 15. [Article]
UniProt
Q05329
PubChem Substance
347909862

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentType 1 Diabetes Mellitus1
3TerminatedTreatmentType 1 Diabetes Mellitus2
2CompletedPreventionImpaired Glucose Tolerance / Type 1 Diabetes Mellitus1
2CompletedTreatmentAutoimmune Disorder / Diabetes Mellitus / Diabetes Mellitus, Insulin Dependent / Diabetes, Autoimmune / Endocrine System Diseases / Immune System Diseases / Metabolic Diseases / Metabolism Disorder, Glucose / Physiological Effects of Drugs / Type 1 Diabetes Mellitus / Vitamin D1
2CompletedTreatmentLatent Autoimmune Diabetes in Adult (LADA)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created at October 21, 2007 22:23 / Updated at September 28, 2023 05:40